TransPRK术后重组人表皮生长因子滴眼液的应用观察

发布时间：2018-03-06 19:31

  本文选题：角膜切削术　切入点：上皮下　出处：《安徽医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的:通过对经角膜上皮的激光角膜切削术(TransPRK)术后疼痛、异物感、角膜上皮愈合情况、裸眼视力、残余等效球镜度等指标的观察,分别评价重组人表皮生长因子滴眼液(rhEGF)应用于TransPRK的临床疗效,为TransPRK术后的合理治疗提供参考依据。方法:选择2015年06月至2015年12月在我院行双眼TransPRK患者,共60例(120只眼),其中女性29例(58只眼),男性31例(62只眼)。将符合入选标准的患者随机分成试验组和对照组。术前均行裸眼视力、矫正视力、眼前节、眼压、角膜曲率、验光、眼底、pentacam角膜地形图、角膜厚度、泪膜破裂时间检查。手术者均是同一人,且严格控制手术室的温度和湿度,以保证激光机的性能维持在最佳状态。术后试验组在常规用药(0.5%左氧氟沙星滴眼液、0.1%氟米龙滴眼液)的基础上加用重组人表皮生长因子滴眼液,对照组常规用药。术后分别于1d、2d、3d、1m、2m、3m时分别评价疼痛、异物感、角膜上皮愈合情况、裸眼视力、角膜上皮下雾状混浊(Haze)、残余等效球镜度(MRSE)指标。数据资料采用±s表示,运用SPSS 16.0软件对数据进行分析,两组数据采用重复测量数据的方差分析。结果:1、除角膜上皮下雾状混浊(Haze)指标外,其它指标的时间差异性均有统计学意义(P0.05)。2、两组间疼痛、角膜上皮愈合在2d、3d有显著差异(Pα'),试验组评分均低于对照组评分;裸眼视力指标在2d、3d有差异(Pα'),且试验组评分均高于对照组评分;其它观察指标均无统计学差异。结论:1、两组的观察指标(除Haze外)均受时间的影响,且随着时间的推移而逐渐好转。2、重组人表皮生长因子滴眼液能够改善早期TransPRK术后患者的部分疼痛症状,能够促进角膜上皮的愈合,提高早期视力,对异物感、Haze、MRSE均无影响。
[Abstract]:Objective: to observe the indexes of pain, foreign body sensation, corneal epithelium healing, naked eyesight, residual equivalent ball endoscopy and so on after TransPRK. To evaluate the clinical efficacy of recombinant human epidermal growth factor eye drops (rhEGF) in the treatment of TransPRK, and to provide reference for reasonable treatment after TransPRK. Methods: from June 2015 to December 2015, patients with binocular TransPRK were selected in our hospital. A total of 120 eyes were found in 60 cases, of which 29 were female (58 eyes) and 31 male (62 eyes). The patients who met the criteria were randomly divided into two groups: the uncorrected visual acuity, corrected visual acuity, anterior segment, intraocular pressure, corneal curvature and optometry. Pentacam corneal topography, corneal thickness, tear film rupture time examination. The operation is the same person, and the temperature and humidity of the operating room are strictly controlled. In order to keep the performance of laser machine in the best condition, the experimental group was treated with recombinant human epidermal growth factor eye drops on the basis of 0.5% levofloxacin eye drops and 0.1% flumilon eye drops. In the control group, pain, foreign body sensation, corneal epithelium healing, uncorrected visual acuity, haze in the subcutaneous haze of cornea, and MRSEs were evaluated at 1 day, 2 days and 3 days after operation, respectively. The data were expressed as 卤s. SPSS 16.0 software was used to analyze the data. Two groups of data were analyzed by the analysis of variance of repeated measurement data. Results: 1. The time difference of other indexes, except for the index of corneal hypodermic haze, was statistically significant (P0.05 路2), and the pain between the two groups was significant. There was significant difference in corneal epithelial healing on the 2nd day and 3rd day, and the scores of the experimental group were lower than those of the control group, and the visual acuity index of the naked eye was different on the 3rd day of the second day, and the score of the test group was higher than that of the control group. Conclusion the observation indexes (except Haze) of the two groups were affected by time. With the passage of time, recombinant human epidermal growth factor eye drops can improve some pain symptoms, promote corneal epithelial healing, improve early visual acuity, and have no effect on foreign body sensation.
【学位授予单位】：安徽医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R779.63
，

本文编号：1576174